Rating Change
Cantor Fitzgerald analysts initiated coverage on AgomAb Therapeutics N.V. American Depositary Shares (NASDAQ:AGMB) with a rating of Overweight on August 19, 2026.
new coverageNASDAQ:AGMB
Cantor Fitzgerald Initiates Coverage on AgomAb Therapeutics N.V. American Depositary Shares (AGMB) with Overweight
Cantor Fitzgerald analysts initiated coverage on AgomAb Therapeutics N.V. American Depositary Shares (NASDAQ:AGMB) with a rating of Overweight on August 19, 2026.
At publication ·
What changed
AgomAb Therapeutics N.V. American Depositary Shares (NASDAQ:AGMB) · new coverage
- Firm
- Cantor Fitzgerald
- Rating
- Overweight
- Price at event
- $13.75
- Market capitalization
- $400.5K
At a glance
Key takeaways
- Cantor Fitzgerald initiated coverage of AgomAb Therapeutics (AGMB) with an Overweight rating on August 19, 2026.
Market Context
AgomAb Therapeutics N.V. American Depositary Shares operates in the Healthcare sector. The stock currently trades at $13.75 with a market capitalization of $400.5K.
Analyst coverage from Cantor Fitzgerald provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for AgomAb Therapeutics N.V. American Depositary Shares.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for AgomAb Therapeutics N.V. American Depositary Shares
Among the 6 most recent ratings: 6 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 19, 2026 | Cantor Fitzgerald | Overweight | N/A |
| Jul 23, 2026 | B. Riley Securities | Buy | N/A |
| Jun 22, 2026 | HC Wainwright & Co. | Buy | N/A |
| Mar 03, 2026 | JP Morgan | Overweight | N/A |
| Mar 03, 2026 | Leerink Partners | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View AGMB Stock Page
Frequently Asked Questions
What does the Overweight rating mean for AGMB?
A rating of Overweight from Cantor Fitzgerald reflects the analyst's outlook on AgomAb Therapeutics N.V. American Depositary Shares (NASDAQ:AGMB). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the AGMB forecast page.